Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data
May 04 2015 - 11:00AM
Business Wire
Agilent Technologies Inc. (NYSE:A) and Cartagenia today
announced that they have signed a definitive agreement under which
Agilent will acquire Cartagenia, a leading provider of software and
services for clinical genetics and molecular pathology labs.
Cartagenia, which has offices in Leuven, Belgium, and Boston,
Massachusetts, provides software solutions for variant assessment
and reporting of clinical genomics data from next-generation
sequencing and microarrays. Uniquely geared to routine clinical
labs, Cartagenia’s solutions are FDA-registered as exempt Class I
Medical Devices in the U.S. and as Class I Medical Devices in
Europe. The Cartagenia Bench platform enables technicians, lab
directors and clinicians to visualize, assess and report clinical
genetics data in the context of patient information.
With Cartagenia Bench, labs can build an internal knowledge
base, build variant assessment SOPs, automate report drafting, and
access a wide range of community-validated, private and premium
content resources, whether for oncology or inherited disease.
Cartagenia’s platform also provides deep support for consortia
of collaborating labs. Data-sharing has become an essential
requirement for the community, and through private and public
consortia, users can connect and pool their knowledge on rare
diseases and actionable findings.
“Cartagenia’s approach to enabling the interpretation of
clinical genomics data is revolutionary,” said Jacob Thaysen,
president of Agilent’s Diagnostics and Genomics Group. “We look
forward to providing Cartagenia’s software solutions to our
clinical genetics and molecular oncology customers and to providing
Cartagenia’s existing customers with access to our global service
and support network. Together, Agilent and Cartagenia can help
remove bottlenecks inherent in analysis, interpretation and
reporting clinical data—resulting in faster answers for
patients.”
“Joining forces with Agilent is an excellent strategic fit and
provides tremendous opportunity both for our customers—who will
benefit from integration with a broad family of solutions and a
range of new applications—and for our team, as we’ll be able to
further accelerate our success and growth through Agilent’s global
reach and leading footprint in clinical labs,” said Herman
Verrelst, chief executive officer, Cartagenia.
The acquisition is expected to be completed May 19, subject to
local laws and regulations and customary closing conditions.
Cartagenia employs 36 people, all of whom will be offered
employment with Agilent.
Financial terms of the transaction were not disclosed.
About Cartagenia
Cartagenia supplies variant assessment support and lab report
automation software, database systems, and related services to
genetic labs, pathology labs and clinicians, enabling them to
perform clinically relevant genetic analyses quickly and
efficiently, and offer patients and carers high-quality genetic
interpretation and counseling.
Cartagenia Bench Lab allows automation of variant assessment
protocols and lab report generation for structural and molecular
variant assays such as Arrays, Sanger and Next Generation
Sequencing. It supports communication with referring physicians,
allows labs and clinicians to put variants in their clinical
context, and supports confident data sharing.
The Cartagenia Bench platform is built in collaboration with
genetics labs and clinical experts involved in routine medical
practice. Because of this, Bench Lab addresses the specific needs
of genetic diagnostic labs and clinicians.
Cartagenia Bench is built using a certified ISO13485 Quality
Management System and is registered with the FDA as an exempt Class
I Medical Device in the United States and as a Class I Medical
Device in Europe in conformity with the essential requirements and
provisions of the Council Directive 93/42/EEC concerning medical
devices, and with the relevant harmonized standards EN
ISO62304.
For more information, visit www.cartagenia.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life
sciences, diagnostics and applied chemical markets, is the premier
laboratory partner for a better world. Agilent works with customers
in more than 100 countries, providing instruments, software,
services and consumables for the entire laboratory workflow.
Agilent generated revenues of $4.0 billion in fiscal 2014. The
company employs about 12,000 people worldwide. Information about
Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
EDITORIAL CONTACTS:Agilent CorporateMichele Drake, +1
408-345-8396michele_drake@agilent.comorAgilent BusinessVictoria
Wadsworth-Hansen, +45 2933
6980victoria.wadsworth-hansen@agilent.comorCartageniaImke
Debeckerimke.debecker@cartagenia.comorINVESTOR
CONTACT:AgilentAlicia Rodriguez, +1
408-345-8948alicia_rodriguez@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024